Foghorn Therapeutics: 5.84M pre-funded warrant shares
Exercise is barred if it would put the reporting persons above 9.99% beneficial ownership; Series 1 expires June 30, 2027, and Series 2 on December 31, 2030.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Foghorn Therapeutics Inc. (FHTX) is the subject of a joint initial ownership report by Mark N. Lampert, listed as a 10% owner, and affiliated investment entities in a Section 13(d) group collectively beneficially owning more than 10% of common stock. As of October 1, 2026, reported Pre-Funded, Series 1 and Series 2 Warrants were exercisable for 5,840,979, 1,835,659 and 1,835,659 shares, respectively. Each class is immediately exercisable subject to a 9.99% beneficial-ownership limit; the reporting persons disclaim beneficial ownership except to the extent of their pecuniary interests.
Insights
Analyzing...
Insider Trade Summary
12 transactions reported
Mixed
12 txns
Insider
BVF PARTNERS L P/IL, BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL, LAMPERT MARK N
Role
10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Pre-Funded Warrants to Purchase Common Stock F1, F5, F2 | -- | -- | -- |
| holding | Pre-Funded Warrants to Purchase Common Stock F1, F5, F3 | -- | -- | -- |
| holding | Pre-Funded Warrants to Purchase Common Stock F1, F5, F4 | -- | -- | -- |
| holding | Series 1 Warrants to Purchase Common Stock F1, F6, F2 | -- | -- | -- |
| holding | Series 1 Warrants to Purchase Common Stock F1, F6, F3 | -- | -- | -- |
| holding | Series 1 Warrants to Purchase Common Stock F1, F6, F4 | -- | -- | -- |
| holding | Series 2 Warrants to Purchase Common Stock F1, F7, F2 | -- | -- | -- |
| holding | Series 2 Warrants to Purchase Common Stock F1, F7, F3 | -- | -- | -- |
| holding | Series 2 Warrants to Purchase Common Stock F1, F7, F4 | -- | -- | -- |
| holding | Common Stock, $0.0001 par value per share F1, F2 | -- | -- | -- |
| holding | Common Stock, $0.0001 par value per share F1, F3 | -- | -- | -- |
| holding | Common Stock, $0.0001 par value per share F1, F4 | -- | -- | -- |
Holdings After Transaction:
Pre-Funded Warrants to Purchase Common Stock — 5,840,979 contracts (Direct);
Series 1 Warrants to Purchase Common Stock — 1,835,659 contracts (Direct);
Series 2 Warrants to Purchase Common Stock — 1,835,659 contracts (Direct);
Common Stock, $0.0001 par value per share — 8,346,168 shares (Direct)
Footnotes (7)
- F1. This Form 3 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
- F2. Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the general parter of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
- F3. Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
- F4. Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
- F5. The Reporting Persons hold certain Pre-Funded Warrants (the "Pre-Funded Warrants") exercisable for an aggregate of 5,840,979 shares of Common Stock. The Pre-Funded Warrants do not expire and have an exercise price of $0.0001 per share. The Pre-Funded Warrants are exercisable immediately, except that the Pre-Funded Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own more than 9.99% of the shares of Common Stock outstanding.
- F6. The Reporting Persons hold certain Series 1 Warrants (the "Series 1 Warrants") exercisable for an aggregate of 1,835,659 shares of Common Stock. The Series 1 Warrants expire on June 30, 2027 and have an exercise price of $13.4200 per share. The Series 1 Warrants are exercisable immediately, except that the Series 1 Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own more than 9.99% of the shares of Common Stock outstanding.
- F7. The Reporting Persons hold certain Series 2 Warrants (the "Series 2 Warrants") exercisable for an aggregate of 1,835,659 shares of Common Stock. The Series 2 Warrants expire on December 31, 2030 and have an exercise price of $20.1300 per share. The Series 2 Warrants are exercisable immediately, except that the Series 2 Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own more than 9.99% of the shares of Common Stock outstanding.
Key Figures
Pre-Funded Warrants exercisable shares: 5,840,979 shares
Series 1 Warrants exercisable shares: 1,835,659 shares
Series 2 Warrants exercisable shares: 1,835,659 shares
+5 more
8 metrics
Pre-Funded Warrants exercisable shares
5,840,979 shares
Aggregate underlying shares
Series 1 Warrants exercisable shares
1,835,659 shares
Aggregate underlying shares
Series 2 Warrants exercisable shares
1,835,659 shares
Aggregate underlying shares
Pre-Funded Warrants exercise price
$0.0001 per share
Exercise price
Series 1 Warrants exercise price
$13.4200 per share
Exercise price
Series 2 Warrants exercise price
$20.1300 per share
Exercise price
Warrant exercise beneficial-ownership limit
9.99%
Exercise is restricted if it would result in beneficial ownership above this level
Series 1 and Series 2 Warrant expiration dates
June 30, 2027; December 31, 2030
Series 1; Series 2, respectively
Key Terms
Pre-Funded Warrants, Series 1 Warrants, Series 2 Warrants, Section 13(d) group, +1 more
5 terms
Pre-Funded Warrants financial
"The Pre-Funded Warrants do not expire"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Series 1 Warrants financial
"The Series 1 Warrants expire on June 30, 2027"
Series 2 Warrants financial
"The Series 2 Warrants expire on December 31, 2030"
Section 13(d) group regulatory
"a member of a Section 13(d) group"
pecuniary interest financial
"to the extent of his or its pecuniary interest therein"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the FHTX warrant exercise prices and expiration dates?
The Pre-Funded Warrants have a $0.0001 per-share exercise price and do not expire. Series 1 Warrants have a $13.4200 per-share exercise price and expire June 30, 2027; Series 2 Warrants have a $20.1300 per-share exercise price and expire December 31, 2030. Each class is immediately exercisable subject to the 9.99% beneficial-ownership limit.
AI-generated analysis. How Rhea-AI works. Not financial advice.
